(Q43263705)

17 November 2017

title

Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial (English)

1 reference

17 November 2017

1 reference

Marc R Toglia

1

1 reference

17 November 2017

Scott R Serels

2

1 reference

17 November 2017

Christine Laramée

3

1 reference

17 November 2017

Mickey M Karram

4

1 reference

17 November 2017

Indrani M Nandy

5

1 reference

17 November 2017

Masakazu Andoh

6

1 reference

17 November 2017

Raafat Seifeldin

7

1 reference

17 November 2017

Sergio Forero-Schwanhaeuser

8

1 reference

17 November 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

17 November 2017

published in

Postgraduate Medicine

1 reference

17 November 2017

volume

121

1 reference

17 November 2017

issue

5

1 reference

17 November 2017

page(s)

151-158

1 reference

The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA.

17 November 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2062

The impact on health‐related quality of life of stress, urge and mixed urinary incontinence

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2062

The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2062

The influence of urinary incontinence on the quality of life of elderly women.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2062

The quality of life in women with urinary incontinence as measured by the sickness impact profile

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2062

Urge incontinence. Quality of life and patients' valuation of symptom reduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2062

Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2062

Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2062

The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2062

The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2062

The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2062

Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2062

A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2062

Validation of the urgency perception scale

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2062

Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2062

Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2062

Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2062

Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2062

Multicenter phase III trial studying trospium chloride in patients with overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2062

Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2062

Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2062

Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2062

Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2062

Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2062

The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2062

Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2062

21 January 2018

Identifiers

DOI

10.3810/PGM.2009.09.2062

1 reference

17 November 2017

1 reference